Early clearance of plasma EGFR mutations as a predictor of response to osimertinib in the AURA3 trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.9027
Abstract: 9027Background: In the Phase III AURA3 trial (NCT02151981), osimertinib, a third-generation EGFR-TKI, had significantly greater efficacy than platinum-pemetrexed in patients (pts) with advanced NSC... read more here.
Keywords: trial; aura3 trial; egfr mutations; early clearance ... See more keywords